358 related articles for article (PubMed ID: 28008176)
41. Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
Chen CC; Parikh K; Abouzaid S; Purnomo L; McGuiness CB; Hussein M; Wade RL
J Manag Care Spec Pharm; 2017 Feb; 23(2):236-246. PubMed ID: 28125372
[TBL] [Abstract][Full Text] [Related]
42. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
[TBL] [Abstract][Full Text] [Related]
43. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.
Warren JL; Harlan LC; Stevens J; Little RF; Abel GA
J Clin Oncol; 2013 Jun; 31(16):1984-9. PubMed ID: 23569317
[TBL] [Abstract][Full Text] [Related]
44. Trends in the incidence and survival of multiple myeloma in South East England 1985-2004.
Renshaw C; Ketley N; Møller H; Davies EA
BMC Cancer; 2010 Mar; 10():74. PubMed ID: 20193064
[TBL] [Abstract][Full Text] [Related]
45. Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains.
Lakdawalla D; Shafrin J; Lucarelli C; Nicholson S; Khan ZM; Philipson TJ
Health Aff (Millwood); 2015 Apr; 34(4):555-61. PubMed ID: 25847636
[TBL] [Abstract][Full Text] [Related]
46. Treatment sequences and drug costs from diagnosis to death in multiple myeloma.
Seefat MR; Cucchi DGJ; Groen K; Donker ML; van der Hem KG; Westerman M; Gerrits AM; Beeker A; van de Donk NWCJ; Blommestein HM; Zweegman S
Eur J Haematol; 2024 Mar; 112(3):360-366. PubMed ID: 37821211
[TBL] [Abstract][Full Text] [Related]
47. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
48. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
Kumar SK; Ma E; Engebretson AE; Buadi FK; Lacy MQ; Dispenzieri A; Duh MS; Lafeuille MH; Lefebvre P; Cheng WY; Dea K; Rembert D; Patt D; Niculescu L; Quick M; Rajkumar SV
Leukemia; 2016 Apr; 30(4):995-8. PubMed ID: 26271606
[No Abstract] [Full Text] [Related]
49. Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
Kumar SK; Majer I; Panjabi S; Medhekar R; Campioni M; Dimopoulos MA
Expert Rev Hematol; 2020 Jun; 13(6):687-696. PubMed ID: 32249621
[TBL] [Abstract][Full Text] [Related]
50. Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany.
Basic E; Kappel M; Misra A; Sellner L; Ratsch BA; Ostwald DA
Eur J Health Econ; 2020 Dec; 21(9):1351-1361. PubMed ID: 32654072
[TBL] [Abstract][Full Text] [Related]
51. Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma.
Coyte PC; Dobrow MJ; Broadfield L
Pharmacoeconomics; 2001; 19(8):845-54. PubMed ID: 11596836
[TBL] [Abstract][Full Text] [Related]
52. The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia.
Rogoff EG; Guirguis HS; Lipton RA; Seremetis SV; DiMichele DM; Agnew GM; Karpatkin M; Barish RJ; Jones RL; Bianco C; Knothe BD; Lee MS
Thromb Haemost; 2002 Oct; 88(4):545-53. PubMed ID: 12362223
[TBL] [Abstract][Full Text] [Related]
53. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.
Rajkumar SV; Harousseau JL
Blood; 2016 Dec; 128(24):2757-2764. PubMed ID: 27742709
[TBL] [Abstract][Full Text] [Related]
54. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Teitelbaum A; Ba-Mancini A; Huang H; Henk HJ
Oncologist; 2013; 18(1):37-45. PubMed ID: 23299776
[TBL] [Abstract][Full Text] [Related]
55. Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape.
Borgsten F; Gatopoulou X; Pisini M; Tambour M; Schain F; Jones CV; Kwok KHM; Batyrbekova N; Björkholm M
Eur J Haematol; 2021 Jul; 107(1):92-103. PubMed ID: 33728732
[TBL] [Abstract][Full Text] [Related]
56. Management of multiple myeloma in Asia: resource-stratified guidelines.
Tan D; Chng WJ; Chou T; Nawarawong W; Hwang SY; Chim CS; Chen W; Durie BG; Lee JH
Lancet Oncol; 2013 Nov; 14(12):e571-81. PubMed ID: 24176575
[TBL] [Abstract][Full Text] [Related]
57. Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality.
Raimundo K; Solomon JJ; Olson AL; Kong AM; Cole AL; Fischer A; Swigris JJ
J Rheumatol; 2019 Apr; 46(4):360-369. PubMed ID: 30442831
[TBL] [Abstract][Full Text] [Related]
58. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
[TBL] [Abstract][Full Text] [Related]
59. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States.
MacEwan JP; Batt K; Yin W; Peneva D; Sison S; Vine S; Chen C
Leuk Lymphoma; 2018 Apr; 59(4):941-949. PubMed ID: 28805105
[TBL] [Abstract][Full Text] [Related]
60. Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan.
Weil C; Gelerstein S; Sharman Moser S; Chodick G; Barit Ben-David N; Shalev V; Shofaniyeh I; Kamalov R; Meytes D
Leuk Res; 2019 Oct; 85():106219. PubMed ID: 31473468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
